Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing - Test2 - elhamkhani - TriplyDB

Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing

Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing

http://www.wikidata.org/entity/Q24632270

about

The Role of PARP Inhibitors in the Treatment of Gynecologic Malignancies Germline ETV6 mutations in familial thrombocytopenia and hematologic malignancy Implications of genetic heterogeneity in cancer Genomic/Epigenomic Alterations in Ovarian Carcinoma: Translational Insight into Clinical Practice Ovarian Cancer and BRCA1/2 Testing: Opportunities to Improve Clinical Care and Disease Prevention Ovarian Cancer: The Fallopian Tube as the Site of Origin and Opportunities for Prevention Confronting the Care Delivery Challenges Arising from Precision Medicine Cancer predisposition genes: molecular mechanisms and clinical impact on personalized cancer care: examples of Lynch and HBOC syndromes The Consequences of a BRCA Mutation in Women Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer Beyond Breast and Ovarian Cancers: PARP Inhibitors for BRCA Mutation-Associated and BRCA-Like Solid Tumors Society of Gynecologic Oncology recommendations for the prevention of ovarian cancer Ovarian cancer biomarker discovery based on genomic approaches PARP Inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study.New perspectives on targeted therapy in ovarian cancer Homologous recombination and human health: the roles of BRCA1, BRCA2, and associated proteins PALB2: the hub of a network of tumor suppressors involved in DNA damage responses Genetic testing for RAD51C mutations: in the clinic and community Contribution of Germline Mutations in the RAD51B, RAD51C, and RAD51D Genes to Ovarian Cancer in the Population Identification of six pathogenic RAD51C mutations via mutational screening of 1228 Danish individuals with increased risk of hereditary breast and/or ovarian cancer Fanconi anaemia and the repair of Watson and Crick DNA crosslinks Systematic screen identifies miRNAs that target RAD51 and RAD51D to enhance chemosensitivity Clinical characteristics of ovarian cancer classified by BRCA1, BRCA2, and RAD51C status Ultra-deep sequencing detects ovarian cancer cells in peritoneal fluid and reveals somatic TP53 mutations in noncancerous tissues Pioneering geneticist Mary-Claire King receives the 2014 Lasker~Koshland Special Achievement Award in Medical Science Fertility-sparing surgery for early stage epithelial ovarian cancer.Rationale for Developing a Specimen Bank to Study the Pathogenesis of High-Grade Serous Carcinoma: A Review of the Evidence Inherited Mutations in Women With Ovarian Carcinoma Hereditary breast cancer: ever more pieces to the polygenic puzzle.Phase I/Ib study of olaparib and carboplatin in BRCA1 or BRCA2 mutation-associated breast or ovarian cancer with biomarker analyses.Germline ETV6 Mutations Confer Susceptibility to Acute Lymphoblastic Leukemia and Thrombocytopenia.Genetic features of myelodysplastic syndrome and aplastic anemia in pediatric and young adult patients.Multi-gene panel testing for hereditary cancer predisposition in unsolved high-risk breast and ovarian cancer patients Integrated analysis of germline and somatic variants in ovarian cancer.Genetic analysis through OtoSeq of Pakistani families segregating prelingual hearing loss Strategies for the Use of Poly(adenosine diphosphate ribose) Polymerase (PARP) Inhibitors in Cancer Therapy.Distinct implications of different BRCA mutations: efficacy of cytotoxic chemotherapy, PARP inhibition and clinical outcome in ovarian cancer Germline and somatic mutations in homologous recombination genes among Chinese ovarian cancer patients detected using next-generation sequencing.

P2860

Q21129302-5D85EF01-B858-4834-A8B6-9F37F6818ADA Q24314163-8CF56C6D-6C1F-4524-9DAD-70B367925934 Q24615812-F1A66DC9-9577-4337-BEC1-B1AF52F8A239 Q26740622-202A1620-F27D-4C8C-9110-D778BAA0D3EF Q26744525-68B4D4CA-2C20-4DA5-A9DF-D06FFD7661C9 Q26747279-9397E804-1D45-4C21-840D-121A4796F7EB Q26747282-9609A022-203E-4F8D-8815-B625DF46577B Q26776258-6F705914-1457-46EA-8480-A99BDBF73562 Q26777891-4C0BA7BB-A38C-4F23-BFDF-B316CB448DC3 Q26783551-1C9C3B7E-1163-4AD3-885E-1A708E60712E Q26852274-B3A9A4E1-00BF-442F-BACA-F8679ACC5CD8 Q27009306-69828C79-5924-41B8-9ABD-F08A5BF520FA Q27013687-89F04EF9-C6FC-4259-B0CC-7352E4B516BA Q27027503-64709701-5FFF-44DE-8E04-63586301581B Q27852671-80348325-063F-4960-90AD-C02ED4E5889D Q27853070-FB08E67F-76EF-41D7-9A85-E4F516B24819 Q28082524-2E38192D-89AE-4CA8-9B02-62A910196276 Q28085364-60F3A889-AA72-421E-A9A4-F3A3755405B0 Q28243398-EA4E2EAC-BA8E-406C-9C7D-996BDAE24A5C Q28253197-5653ACBC-2804-433C-B2CB-01453BA17407 Q28266112-7C991E00-91E7-4475-8171-8293D7EF6C13 Q28271817-CC5C7022-1446-41BE-8E50-5241813CDDF3 Q28283549-24E4EA78-C94A-4C2B-AA6D-8C284227F4C1 Q28299698-DADD418A-C8F5-41AF-B7AF-E399BC23DD9D Q28307436-63EA751A-8F63-4AD0-8CBC-A1C6C4D51EF3 Q28395740-D7DC6F80-826A-47DE-836C-CE6B40967E6C Q28654820-81A30F3F-B013-4F54-B8CB-FDB873240D7B Q30249715-D709B980-A6BF-4E80-931E-94A3E2C6C729 Q30250107-09AE8DF7-9DD2-49AA-9BC4-6B20245E94F7 Q30353433-936E5262-D209-4FA2-A6C6-495AFA0FBCC7 Q33356511-11DA661E-6ABD-42EB-B706-B254F196ECA0 Q33415400-101A2433-555F-45B9-8A6A-DAC50D547A69 Q33423823-1679D8A6-E8B6-4FC0-BD44-2491B3E451BC Q33573503-9EA5974D-32CB-4003-BBE2-7172F524C607 Q33618262-A108DFFA-C584-4864-9BFB-56CF0F6B30BB Q33630954-54AD3DA1-84FA-4D45-8534-B3529F4E7653 Q33647400-5F5384E7-8B70-4D7C-85BB-41984F224816 Q33649555-DDAFD556-F3AE-49B3-AF00-D108769DA948 Q33704050-9919072A-C868-4753-A660-5B16ACF9E788 Q33735109-00EEB30F-7509-4C1F-87D6-671B6B31CF5F

P2860

Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing

http://www.wikidata.org/entity/Q24632270

description

2011 nî lūn-bûn

@nan

2011 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Mutations in 12 genes for inhe ...... massively parallel sequencing

@ast

Mutations in 12 genes for inhe ...... massively parallel sequencing

@en

Mutations in 12 genes for inhe ...... massively parallel sequencing

@nl

type

label

Mutations in 12 genes for inhe ...... massively parallel sequencing

@ast

Mutations in 12 genes for inhe ...... massively parallel sequencing

@en

Mutations in 12 genes for inhe ...... massively parallel sequencing

@nl

prefLabel

Mutations in 12 genes for inhe ...... massively parallel sequencing

@ast

Mutations in 12 genes for inhe ...... massively parallel sequencing

@en

Mutations in 12 genes for inhe ...... massively parallel sequencing

@nl

P1433

Q24632270-9CC0415F-C223-4F5D-A9E0-D2AFC51E693D

P1476

Q24632270-C4BE12EC-A4B7-4AB1-9ABF-5DDE294FDDE6

P2093

Q24632270-09662E31-C8EB-41B0-B3E8-BC5FCC0362C6

Q24632270-0C5CF260-CFF1-495F-86C9-6389DFF2DFFB

Q24632270-19ADA7E6-AB54-439A-B74C-D0EB50B01CE3

Q24632270-1AFD9E4C-8865-4B3C-A6BB-30C0F9E11579

Q24632270-28720C04-EEDD-434A-AD7B-69A916463F70

Q24632270-67FCB0D3-CF42-445F-9956-AC8D12FA2158

Q24632270-6A270F7C-96CB-4EF3-8550-BD17D67C0C17

Q24632270-6A4DAF80-CC3E-420E-A194-23CD1CB38D72

Q24632270-7CFE6FC9-295C-44CC-A8D3-3C8AD6113914

Q24632270-9ED916E7-9B25-4CE7-8328-4A429ADBBBA3

P2860

Q24632270-08D6AE7F-D836-4551-B26B-B563A6FEBA27

Q24632270-185D06CD-B0F2-4A47-9491-6A6726455474

Q24632270-22620CD3-C4B8-4984-BA12-6C2248348EF7

Q24632270-288135CE-ABB6-44EA-AD6F-95CBB9D11A09

Q24632270-34DFD10A-7511-4F50-A644-AFD5A7F8259C

Q24632270-4AABB398-1E53-46DD-B31F-4D9A31DE7559

Q24632270-5151EB22-228B-4A13-9EB4-BF763E9824FC

Q24632270-53C069F1-8F19-48E7-B3A5-F85396908005

Q24632270-58F40915-1B93-4FF9-BC5E-03C36B959409

Q24632270-633A7F50-5641-4C11-982D-EDB2B462906C

P304

Q24632270-0DBB82C1-5704-406D-8068-ED99FCA976F2

P31

Q24632270-7611A701-4EC5-426A-A18E-4898D4EE0FFE

P3181

Q24632270-3B65B7C4-5033-4FB4-8A1F-300272BAFF40

P356

Q24632270-D6BDFB32-A45A-4889-AB5A-573F07A9F4C4

P407

Q24632270-E24E0D88-7BBB-4F5B-B8DC-4729EB06653F

P433

Q24632270-0EED60CE-4696-438A-9746-64A6BFE2C0D8

P478

Q24632270-60895D66-46B4-4889-8D8F-D2471DA57C13

P50

Q24632270-36AA7C5F-4AF1-4DCF-9457-EEADCC8D5B1A

Q24632270-801468A8-F327-46D4-83D2-29C7547B4475

Q24632270-94B4E2DB-A42D-407B-9C55-D2699ACD5C41

Q24632270-9CBD1334-5FD8-4A9D-A1E8-F3209FA271AE

P577

Q24632270-FF5431AF-A3DE-4711-A1B4-EA201616B269

P5875

Q24632270-D7102C14-FC15-479F-9FD9-36586D188912

P698

Q24632270-63738BC5-7615-42E3-934A-BFB41E0889DD

P921

Q24632270-AD748674-274A-4C2C-B9C9-2EBA34E18207

P932

Q24632270-0EC500A9-A08D-424F-9670-9BCCB5351F49

P3181

P356

PNAS.1115052108

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Mutations in 12 genes for inhe ...... massively parallel sequencing

@en

P2093

Anne M Thornton

http://www.w3.org/2001/XMLSchema#string

Anneka Wickramanayake

http://www.w3.org/2001/XMLSchema#string

Christopher C Pennil

http://www.w3.org/2001/XMLSchema#string

Elizabeth M Swisher

http://www.w3.org/2001/XMLSchema#string

Kathryn P Pennington

http://www.w3.org/2001/XMLSchema#string

Kathy J Agnew

http://www.w3.org/2001/XMLSchema#string

Ming K Lee

http://www.w3.org/2001/XMLSchema#string

Rochelle L Garcia

http://www.w3.org/2001/XMLSchema#string

Silvia Casadei

http://www.w3.org/2001/XMLSchema#string

Sunday M Stray

http://www.w3.org/2001/XMLSchema#string

P2860

Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals

Detection of inherited mutations for breast and ovarian cancer using genomic capture and massively parallel sequencing

Susceptibility pathways in Fanconi's anemia and breast cancer

Results from four rounds of ovarian cancer screening in a randomized trial

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.

Integrated genomic analyses of ovarian carcinoma

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase

Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2

Germline mutations in RAD51D confer susceptibility to ovarian cancer

P304

18032-7

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

594494

http://www.w3.org/2001/XMLSchema#string

P356

10.1073/PNAS.1115052108

http://www.w3.org/2001/XMLSchema#string

P407

P433

44

http://www.w3.org/2001/XMLSchema#string

P478

108

http://www.w3.org/2001/XMLSchema#string

P50

Mary-Claire King

Barbara Norquist

P577

2011-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51725957

http://www.w3.org/2001/XMLSchema#string

P698

22006311

http://www.w3.org/2001/XMLSchema#string

P921

P932

3207658

http://www.w3.org/2001/XMLSchema#string